Macroautophagy(referred to as autophagy hereafter)is a major intracellular lysosomal degradation pathway that is responsible for the degradation of misfolded/damaged proteins and organelles.Previous studies showed tha...Macroautophagy(referred to as autophagy hereafter)is a major intracellular lysosomal degradation pathway that is responsible for the degradation of misfolded/damaged proteins and organelles.Previous studies showed that autophagy protects against acetaminophen(APAP)-induced injury(AILI)via selective removal of damaged mitochondria and APAP protein adducts.The lysosome is a critical organelle sitting at the end stage of autophagy for autophagic degradation via fusion with autophagosomes.In the present study,we showed that transcription factor EB(TFEB),a master transcription factor for lysosomal biogenesis,was impaired by APAP resulting in decreased lysosomal biogenesis in mouse livers.Genetic loss-of and gain-of function of hepatic TFEB exacerbated or protected against AILI,respectively.Mechanistically,overexpression of TFEB increased clearance of APAP protein adducts and mitochondria biogenesis as well as SQSTM1/p62-dependent non-canonical nuclear factor erythroid 2-related factor 2(NRF2)activation to protect against AILI.We also performed an unbiased cell-based imaging high-throughput chemical screening on TFEB and identified a group of TFEB agonists.Among these agonists,salinomycin,an anticoccidial and antibacterial agent,activated TFEB and protected against AILI in mice.In conclusion,genetic and pharmacological activating TFEB may be a promising approach for protecting against AILI.展开更多
Sepsis is an overwhelming inflammatory response to microbial infection.Sepsis management remains a clinical challenge.The role of the gut microbiome in sepsis has gained some attention.Recent evidence has demonstrated...Sepsis is an overwhelming inflammatory response to microbial infection.Sepsis management remains a clinical challenge.The role of the gut microbiome in sepsis has gained some attention.Recent evidence has demonstrated that gut microbiota regulate host physiological homeostasis mediators,including the immune system,gut barrier function and disease susceptibility pathways.Therefore,maintenance or restoration of microbiota and metabolite composition might be a therapeutic or prophylactic target against critical illness.Fecal microbiota transplantation and supplementation of probiotics are microbiota-based treatment methods that are somewhat limited in terms of evidence-based efficacy.This review focuses on the importance of the crosstalk between the gastrointestinal ecosystem and sepsis to highlight novel microbiota-targeted therapies to improve the outcomes of sepsis treatment.展开更多
基金We would like to thank Dr.Thomas Ru¨licke at Department of Biomedical Sciences,University of Veterinary Medicine Vienna,Vienna,Austria and Dr.Kurt Zatloukal at The Institute of Pathology,Medical University of Graz,A-8036 Graz,Austria for providing us whole body Sqstm1/p62 knockout mice for the hepatocyte isolation experiment.We also thank Larysa Stroganova at University of Kansas Medical Center for her excellent assistance for the EM studies.This study was supported in part by the National Institute of Health(NIH,USA)funds R01 DK102142,R01 AG072895,R37 AA020518(WXD)and in part by the Intramural Research Program of the National Center for Advancing Translational Sciences,NIH(USA).
文摘Macroautophagy(referred to as autophagy hereafter)is a major intracellular lysosomal degradation pathway that is responsible for the degradation of misfolded/damaged proteins and organelles.Previous studies showed that autophagy protects against acetaminophen(APAP)-induced injury(AILI)via selective removal of damaged mitochondria and APAP protein adducts.The lysosome is a critical organelle sitting at the end stage of autophagy for autophagic degradation via fusion with autophagosomes.In the present study,we showed that transcription factor EB(TFEB),a master transcription factor for lysosomal biogenesis,was impaired by APAP resulting in decreased lysosomal biogenesis in mouse livers.Genetic loss-of and gain-of function of hepatic TFEB exacerbated or protected against AILI,respectively.Mechanistically,overexpression of TFEB increased clearance of APAP protein adducts and mitochondria biogenesis as well as SQSTM1/p62-dependent non-canonical nuclear factor erythroid 2-related factor 2(NRF2)activation to protect against AILI.We also performed an unbiased cell-based imaging high-throughput chemical screening on TFEB and identified a group of TFEB agonists.Among these agonists,salinomycin,an anticoccidial and antibacterial agent,activated TFEB and protected against AILI in mice.In conclusion,genetic and pharmacological activating TFEB may be a promising approach for protecting against AILI.
基金supported by National Natural Science Foundation of China(81873926)to PC。
文摘Sepsis is an overwhelming inflammatory response to microbial infection.Sepsis management remains a clinical challenge.The role of the gut microbiome in sepsis has gained some attention.Recent evidence has demonstrated that gut microbiota regulate host physiological homeostasis mediators,including the immune system,gut barrier function and disease susceptibility pathways.Therefore,maintenance or restoration of microbiota and metabolite composition might be a therapeutic or prophylactic target against critical illness.Fecal microbiota transplantation and supplementation of probiotics are microbiota-based treatment methods that are somewhat limited in terms of evidence-based efficacy.This review focuses on the importance of the crosstalk between the gastrointestinal ecosystem and sepsis to highlight novel microbiota-targeted therapies to improve the outcomes of sepsis treatment.
